• NF 340: A Selective P2Y11 Antagonist for Cancer & Immunology

  2026-04-22

  NF 340 stands out as a research-grade, highly selective P2Y11 antagonist, enabling precise modulation of purinergic GPCR signaling in cutting-edge cancer and immunology models. Applied protocols and troubleshooting strategies unlock new depth in inflammation pathway analysis and breast cancer invasion assays.

• Bismuth Subsalicylate: Technical Guidance for GI Disorder Re

  2026-04-22

  Bismuth Subsalicylate (SKU A8382) is used to investigate gastrointestinal disorder mechanisms, focusing on inflammation modulation and diarrhea treatment research. This compound is not suitable for diagnostic or therapeutic applications, and its workflow is dictated by solubility and stability constraints outlined in the product specification.

• Ordered DNA Nanostructures Enhance Enzymatic DNA Synthesis E

  2026-04-21

  This study introduces a three-dimensional tetrahedral DNA nanostructure (TDN) as a scaffold to improve enzymatic oligonucleotide synthesis (EOS). By optimizing primer orientation and spacing, the TDN interface increases enzyme accessibility and reduces synthesis errors, offering significant advantages for DNA information storage and advanced molecular biology applications.

• Carfilzomib (PR-171): Irreversible Proteasome Inhibition in

  2026-04-21

  Carfilzomib (PR-171) is a highly potent, irreversible proteasome inhibitor used in cancer research to induce apoptosis via selective inhibition of chymotrypsin-like proteasome activity. It demonstrates subnanomolar IC50 values in cell-based assays and is effective in translational models of tumor growth suppression. This article details the mechanism, evidence, and laboratory integration of APExBIO’s Carfilzomib (PR-171).

• Refining In Vitro Drug Evaluation in Cancer: Insights from S

  2026-04-20

  Schwartz et al. (2022) systematically dissect how in vitro assays distinguish between cell proliferation arrest and cell death when evaluating anti-cancer drugs. Their work emphasizes the importance of using both relative and fractional viability metrics to accurately interpret drug responses. These findings inform best practices for preclinical drug screening and benchmarking of cell cycle checkpoint inhibitors.

• Anlotinib Hydrochloride: Mechanism, Validation, and Strategi

  2026-04-20

  This thought-leadership article examines the mechanistic depth and translational strategies surrounding Anlotinib hydrochloride, a next-generation multi-target tyrosine kinase inhibitor. Drawing on definitive preclinical evidence and contextualizing the molecule within the current competitive landscape, we offer actionable guidance for translational researchers aiming to advance angiogenesis-focused cancer research. The discussion bridges rigorous biological rationale, validated experimental protocols, and forward-looking perspectives, establishing new standards for leveraging Anlotinib hydrochloride in both discovery and translational workflows.

• NSC-23766: Rac GTPase Inhibitor for Applied Cancer Research

  2026-04-19

  NSC-23766 empowers researchers to dissect Rac1-driven pathways with unparalleled selectivity, driving advances in cancer biology and barrier function studies. This guide delivers actionable workflows, troubleshooting insights, and key innovations informed by the latest research on Rac1 signaling modulation.

• Necrostatin-1: Applied RIP1 Kinase Inhibition in Necroptosis

  2026-04-18

  Necrostatin-1 empowers researchers to dissect necroptosis with precision, offering unrivaled selectivity as a RIP1 kinase inhibitor. This guide translates recent mechanobiology insights and workflow advances into actionable protocols for acute injury and cancer models.

• Dissecting In Vitro Drug Response: Lessons from Fractional V

  2026-04-17

  Schwartz's dissertation introduces a nuanced framework to distinguish drug-induced cell death from proliferative arrest in cancer research, establishing the importance of fractional viability analysis. These findings inform more precise evaluation of tyrosine kinase inhibitors like Tivozanib in in vitro oncology workflows.

• VX-765: Potent Caspase-1 Inhibitor for Inflammation Research

  2026-04-16

  VX-765 is a potent, orally absorbed caspase-1 inhibitor that selectively suppresses IL-1β and IL-18 release while sparing unrelated cytokines. This selectivity makes VX-765 an essential tool for dissecting inflammasome signaling and pyroptosis, particularly in macrophage and T-cell models. Extensive benchmarks validate its efficacy in rheumatoid arthritis and HIV-related CD4 T-cell pyroptosis studies.

• Dabigatran Etexilate: Advancing Oral Anticoagulation Therapy

  2026-04-15

  This clinical review evaluates dabigatran etexilate, the first oral direct thrombin inhibitor approved for stroke and venous thromboembolism (VTE) prevention. The paper addresses the limitations of traditional anticoagulants and demonstrates how dabigatran offers rapid, predictable effects without the monitoring challenges of vitamin K antagonists, supporting safer and more accessible thromboprophylaxis.

• AICAR Phosphate: Beyond B-CLL—AMPK Activation for Mitochondr

  2026-04-14

  Explore the unique role of AICAR phosphate (Acadesine) as an AMPK activator, not only as a B-CLL apoptosis inducer but also as a tool for probing mitochondrial quality control and inflammation. Discover mechanistic insights and practical guidance distinct from prior B-CLL-centered resources.

• Large-Scale Gastruloid Arrays for Phenotype Screening in Dev

  2026-04-13

  Jan et al. (2025) introduce an automated microraft array platform enabling high-throughput image-based screening and sorting of human gastruloids, capturing phenotypic heterogeneity in early development. Their approach advances the study of chromosomal abnormalities and spatial gene expression during gastrulation, facilitating single-gastruloid molecular analysis.

• AICAR-Driven AMPK Activation: Strategic Leverage in Metaboli

  2026-04-13

  This thought-leadership article explores how AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) uniquely empowers translational researchers to dissect and modulate energy metabolism, inflammation, and cellular stress responses. Grounded in mechanistic insights and the latest literature—including recent work on mitophagy in sarcopenic obesity—this piece goes beyond conventional product summaries, offering strategic guidance for experimental design, validation, and interpretation. Protocol parameters, evidence labeling, and competitive context are provided to help researchers maximize the translational impact of AICAR-enabled studies.

• Repurposing Lopinavir: Inhibition of MERS-CoV in Cell Cultur

  2026-04-12

  de Wilde et al. conducted a systematic screen of FDA-approved drugs, identifying Lopinavir (ABT-378) among four small molecules capable of inhibiting MERS-CoV replication at low micromolar concentrations in cell models. This study highlights the potential of protease inhibitors, traditionally used in HIV research, for rapid-response antiviral strategies against emerging coronaviruses.

14923 records 1/995 page Next 12345 下5页 Last page